12:00 AM
 | 
Oct 05, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

RVX-208: Additional Phase Ib/IIa data

Additional data from a double-blind, Phase Ib/IIa trial in 72 subjects, about half of whom had low levels of baseline HDL cholesterol, showed that 1mg/kg RVX-208 twice daily led to plasma APOA1 increases of 5.7% and 7.8% vs. placebo at days...

Read the full 181 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >